Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist

eLife

Volumn 5, Issue APRIL2016, 2016, Pages

  Damond, Nicolas ^a   Thorel, Fabrizio ^a   Moyers, Julie S ^b   Charron, Maureen J ^c   Vuguin, Patricia M ^d   Powers, Alvin C ^e,f   Herrera, Pedro L ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b ELI LILLY AND COMPANY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Columbia University ^*  (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f VA Tennessee Valley Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; DOXYCYCLINE; GLUCAGON; GLUCAGON RECEPTOR; GLYCOGEN; HYPERGLYCEMIC AGENT; INSULIN; INSULIN DETEMIR; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; S961; STREPTOZOCIN; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TOLERANCE TEST; MALE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL HYPERPLASIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; ANIMAL; DEFICIENCY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GASTROINTESTINAL AGENTS; GLUCAGON; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, KNOCKOUT; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 84971578289     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.13828     Document Type: Article

References (52)

1. Ali S, Lamont BJ, Charron MJ, Drucker DJ. 2011. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. The Journal of Clinical Investigation 121:1917–1929. doi: 10.1172/JCI43615
2. Brand CL, Rolin B, Jørgensen PN, Svendsen I, Kristensen JS, Holst JJ. 1994. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37:985–993. doi: 10.1007/bf00400461
3. Campbell JE, Drucker DJ. 2015. Islet alpha cells and glucagon–critical regulators of energy homeostasis. Nature Reviews. Endocrinology 11:329–338. doi: 10.1038/nrendo.2015.51
4. Cardinal JW, Allan DJ, Cameron DP. 1998. Differential metabolite accumulation may be the cause of strain differences in sensitivity to streptozotocin-induced beta cell death in inbred mice. Endocrinology 139:2885–2891. doi: 10.1210/endo.139.6.6048
5. Chakravarty K, Cassuto H, Reshef L, Hanson RW. 2005. Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-c. Critical Reviews in Biochemistry and Molecular Biology 40: 129–154. doi: 10.1080/10409230590935479
6. Chera S, Baronnier D, Ghila L, Cigliola V, Jensen JN, Gu G, Furuyama K, Thorel F, Gribble FM, Reimann F, Herrera PL. 2014. Diabetes recovery by age-dependent conversion of pancreatic delta cells into insulin producers. Nature 514:503–507. doi: 10.1038/nature13633
7. Conarello SL, Jiang G, Mu J, Li Z, Woods J, Zycband E, Ronan J, Liu F, Roy RS, Zhu L, Charron MJ, Zhang BB. 2007. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50:142–150. doi: 10.1007/s00125-006-0481-3
8. D’Alessio D. 2011. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes, Obesity and Metabolism 13:126–132. doi: 10.1111/j.1463-1326.2011.01449.x
9. Deeds MC, Anderson JM, Armstrong AS, Gastineau DA, Hiddinga HJ, Jahangir A, Eberhardt NL, Kudva YC. 2011. Single dose streptozotocin-induced diabetes: Considerations for study design in islet transplantation models. Laboratory Animals 45:131–140. doi: 10.1258/la.2010.010090
10. Desgraz R, Herrera PL. 2009. Pancreatic neurogenin 3-expressing cells are unipotent islet precursors. Development 136:3567–3574. doi: 10.1242/dev.039214
11. Furuta M, Yano H, Zhou A, Rouille Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, Steiner DF. 1997. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proceedings of the National Academy of Sciences of the United States of America 94:6646–6651. doi: 10.1073/pnas.94.13.6646
12. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ. 2003. Lower blood glucose, hyperglucagonemia, and pancreatic cell hyperplasia in glucagon receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 100:1438–1443. doi: 10.1073/pnas.0237106100
13. Gromada J, Franklin I, Wollheim CB. 2007. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocrine Reviews 28:84–116. doi: 10.1210/er.2006-0007
14. Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, Sivits G, Hill D, Yang J, Bi V, Shen Y, Hu S, Boone T, Lindberg RA, Véniant MM. 2009. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. The Journal of Pharmacology and Experimental Therapeutics 331:871–881. doi: 10.1124/jpet.109.157685
15. Gu W, Winters KA, Motani AS, Komorowski R, Zhang Y, Liu Q, Wu X, Rulifson IC, Sivits G, Graham M, Yan H, Wang P, Moore S, Meng T, Lindberg RA, Veniant MM. 2010. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor. AJP: Endocrinology and Metabolism 299:E624–E632. doi: 10.1152/ajpendo.00102.2010
16. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM. 2006. Impact of genetic background on nephropathy in diabetic mice. AJP: Renal Physiology 290:F214–F222. doi: 10.1152/ajprenal.00204.2005
17. Hancock AS, Du A, Liu J, Miller M, May CL. 2010. Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Molecular Endocrinology 24:1605–1614. doi: 10.1210/me.2010-0120
18. Iynedjian PB, Marie S, Gjinovci A, Genin B, Deng SP, Buhler L, Morel P, Mentha G. 1995. Glucokinase and cytosolic phosphoenolpyruvate carboxykinase (GTP) in the human liver. regulation of gene expression in cultured hepatocytes. The Journal of Clinical Investigation 95:1966–1973. doi: 10.1172/JCI117880
19. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D. 1982. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215:1115–1116. doi: 10.1126/science.6278587
20. Jun LS. 2014. Absence of glucagon and insulin action reveals a role for the glucagon-like peptide-1 receptor in endogenous glucose production. Diabetes. doi: 10.2337/db14-1052
21. Kelly RP, Garhyan P, Raddad E, Fu H, Lim CN, Prince MJ, Pinaire JA, Loh MT, Deeg MA. 2015. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes, Obesity and Metabolism 17:414–422. doi: 10.1111/dom.12446
22. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. 2011. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60:391–397. doi: 10.2337/db10-0426
23. Lee Y, Berglund ED, Wang M.-y., Fu X, Yu X, Charron MJ, Burgess SC, Unger RH. 2012. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proceedings of the National Academy of Science of the Uunited States of America 109:14972–14976. doi: 10.1073/pnas.1205983109
24. Long YC, Cheng Z, Copps KD, White MF. 2011. Insulin receptor substrates irs1 and irs2 coordinate skeletal muscle growth and metabolism via the akt and AMPK pathways. Molecular and Cellular Biology 31:430–441. doi: 10.1128/MCB.00983-10
25. Longuet C, Robledo AM, Dean ED, Dai C, Ali S, McGuinness I, de Chavez V, Vuguin PM, Charron MJ, Powers AC, Drucker DJ. 2013. Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: Evidence for a circulating alpha-cell growth factor. Diabetes 62:1196–1205. doi: 10.2337/db11-1605
26. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. 2005. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: Indirect evidence for islet regeneration? Diabetologia 48:2221–2228. doi: 10.1007/s00125-005-1949-2
27. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. 2000. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Molecular Cell 6:87–97. doi: 10.1016/s1097-2765(05)00015-8
28. Mu J, Jiang G, Brady E, Dallas-Yang Q, Liu F, Woods J, Zycband E, Wright M, Li Z, Lu K, Zhu L, Shen X, Sinharoy R, Candelore ML, Qureshi SA, Shen DM, Zhang F, Parmee ER, Zhang BB. 2011. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia 54:2381–2391. doi: 10.1007/s00125-011-2217-2
29. Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahrén B. 2014. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 63: 101–110. doi: 10.2337/db13-0710
30. Ouhilal S, Vuguin P, Cui L, Du X-Q, Gelling RW, Reznik SE, Russell R, Parlow AF, Karpovsky C, Santoro N, Charron MJ. 2012. Hypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: A role for glucagon action in pregnancy maintenance. AJP: Endocrinology and Metabolism 302:E522–E531. doi: 10.1152/ajpendo.00420.2011
31. Perl A-KT, Wert SE, Nagy A, Lobe CG, Whitsett JA. 2002. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proceedings of the National Academy of Sciences of the United States of America 99:10482–10487. doi: 10.1073/pnas.152238499
32. Rucktäschel AK, Granner DK, Christ B. 2000. Regulation by glucagon (camp) and insulin of the promoter of the human phosphoenolpyruvate carboxykinase gene (cytosolic) in cultured rat hepatocytes and in human hepatoblastoma cells. The Biochemical Journal 352 Pt 1:211–217. doi: 10.1042/bj3520211
33. Schäffer L, Brand CL, Hansen BF, Ribel U, Shaw AC, Slaaby R, Sturis J. 2008. A novel high-affinity peptide antagonist to the insulin receptor. Biochemical and Biophysical Research Communications 376:380–383. doi: 10.1016/j.bbrc.2008.08.151
34. Sherwin RS, Fisher M, Hendler R, Felig P. 1976. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. The New England Journal of Medicine 294:455–461. doi: 10.1056/NEJM197602262940901
35. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, Jacobs SJ, Moyers JS, Owens RA, Showalter AD, Brenner MB, Raap A, Gromada J, Berridge BR, Monteith DK, Porksen N, McKay RA, Monia BP, Bhanot S, Watts LM, et al. 2004. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. The Journal of Clinical Investigation 113:1571–1581. doi: 10.1172/JCI20911
36. Sørensen H, Brand CL, Neschen S, Holst JJ, Fosgerau K, Nishimura E, Shulman GI. 2006. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 55:2843–2848. doi: 10.2337/db06-0222
37. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, Costantini F. 2001. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Developmental Biology 1:4.
38. Steenberg VR, Jensen SM, Pedersen J, Madsen AN, Windeløv JA, Holst B, Quistorff B, Poulsen SS, Holst JJ. 2016. Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. Diabetologia 59:363–370. doi: 10.1007/s00125-015-3794-2
39. Strom A, Bonal C, Ashery-Padan R, Hashimoto N, Campos ML, Trumpp A, Noda T, Kido Y, Real FX, Thorel F, Herrera PL. 2007. Unique mechanisms of growth regulation and tumor suppression upon apc inactivation in the pancreas. Development 134:2719–2725. doi: 10.1242/dev.02875
40. Thorel F, Népote V, Avril I, Kohno K, Desgraz R, Chera S, Herrera PL. 2010. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464:1149–1154. doi: 10.1038/nature08894
41. Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM. 1970. Studies of pancreatic alpha cell function in normal and diabetic subjects. The Journal of Clinical Investigation 49:837–848. doi: 10.1172/JCI106297
42. Unger RH. 1971. Glucagon physiology and pathophysiology. The New England Journal of Medicine 285:443–449. doi: 10.1056/NEJM197108192850806
43. Unger RH, Orci L. 2010. Paracrinology of islets and the paracrinopathy of diabetes. Proceedings of the National Academy of Sciences of the United States of America 107:16009–16012. doi: 10.1073/pnas.1006639107
44. Unger RH, Cherrington AD. 2012. Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. The Journal of Clinical Investigation 122:4–12. doi: 10.1172/JCI60016
45. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3:research0034.1–research0034. 0011. doi: 10.1186/gb-2002-3-7-research0034
46. Vuguin PM, Kedees MH, Cui L, Guz Y, Gelling RW, Nejathaim M, Charron MJ, Teitelman G. 2006. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 147:3995–4006. doi: 10.1210/en.2005-1410
47. Vuguin PM, Charron MJ. 2011. Novel insight into glucagon receptor action: Lessons from knockout and transgenic mouse models. Diabetes, Obesity and Metabolism 13:144–150. doi: 10.1111/j.1463-1326.2011.01447.x
48. Wang L, Lovejoy NF, Faustman DL. 2012. Persistence of prolonged c-peptide production in type 1 diabetes as measured with an ultrasensitive c-peptide assay. Diabetes Care 35:465–470. doi: 10.2337/dc11-1236
49. Wang M-Y, Yan H, Shi Z, Evans MR, Yu X, Lee Y, Chen S, Williams A, Philippe J, Roth MG, Unger RH. 2015. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proceedings of the National Academy of Sciences of the United States of America 112:2503–2508. doi: 10.1073/pnas.1424934112
50. Yan H, Gu W, Yang J, Bi V, Shen Y, Lee E, Winters KA, Komorowski R, Zhang C, Patel JJ, Caughey D, Elliott GS, Lau YY, Wang J, Li YS, Boone T, Lindberg RA, Hu S, Ve´ niant MM. 2009. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. The Journal of Pharmacology and Experimental Therapeutics 329:102–111. doi: 10.1124/jpet.108.147009
51. Yang J, MacDougall ML, McDowell MT, Xi L, Wei R, Zavadoski WJ, Molloy MP, Baker JD, Kuhn M, Cabrera O, Treadway JL. 2011. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: Implications on anti-glucagon therapies for diabetes. BMC Genomics 12:281. doi: 10.1186/1471-2164-12-281
52. Yi P, Park JS, Melton DA. 2013. Betatrophin: A hormone that controls pancreatic beta cell proliferation. Cell 153: 747–758. doi: 10.1016/j.cell.2013.04.008